Zimmer Biomet
ZBH
870 hedge funds and large institutions have $21.2B invested in Zimmer Biomet in 2017 Q4 according to their latest regulatory filings, with 116 funds opening new positions, 293 increasing their positions, 284 reducing their positions, and 60 closing their positions.
93% more first-time investments, than exits
New positions opened: 116 | Existing positions closed: 60
73% more call options, than puts
Call options by funds: $113M | Put options by funds: $65.5M
7% more funds holding in top 10
Funds holding in top 10: 15 → 16 (+1)
6% more funds holding
Funds holding: 818 → 870 (+52)
3% more repeat investments, than reductions
Existing positions increased: 293 | Existing positions reduced: 284
3% more capital invested
Capital invested by funds: $20.6B → $21.2B (+$646M)
0.08% less ownership
Funds ownership: 89.5% → 89.42% (-0.08%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$542M |
| 2 |
Goldman Sachs
New York
|
+$139M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$125M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$118M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$78.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Glenview Capital Management
New York
|
-$369M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$177M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$168M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$119M |
| 5 |
JP
Jana Partners
New York
|
-$94.1M |
ZBH Hedge Fund Activity: Q4 2017 in Review
870 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Zimmer Biomet (ZBH) for Q4 2017, worth a combined $21.2B — up 3.1% from $20.6B a quarter earlier.
Buyers outnumbered sellers: 116 funds opened new ZBH positions and 60 closed out — a net gain of 56 holders — while 293 added to existing stakes and 284 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $542M. The largest seller was Glenview Capital Management, exiting entirely with an estimated $369M sold.
- 870 institutional investors held Zimmer Biomet (ZBH) as of Q4 2017, up from 818 in Q3 2017.
- Funds reported $21.2B of Zimmer Biomet stock for Q4 2017, up 3.1% quarter-over-quarter.
- 116 funds opened new Zimmer Biomet positions in Q4 2017 and 60 closed out, a net change of +56 holders.
- The largest Zimmer Biomet buyer in Q4 2017 was JP Morgan Chase, an estimated $542M added.
- The largest Zimmer Biomet seller in Q4 2017 was Glenview Capital Management, an estimated $369M sold.
Based on aggregated 13F filings for Q4 2017.